On the World Diabetes Day, Diamyd Medical will host a live moderated discussion featuring leading experts in Type 1 Diabetes research and advocacy. The session will explore how advances in immune tolerance and precision medicine are driving the transition from symptom management to true disease modification in type 1 diabetes.

The panel includes:

• Professor Johnny Ludvigsson, Linköping University
• Professor Åke Lernmark, Lund University
• Joshua Vieth, Senior Director, Breakthrough T1D, US
• Ulf Hannelius, CEO, Diamyd Medical, Stockholm

“World Diabetes Day is an opportunity to highlight the progress being made toward changing the outlook for people with Type 1 Diabetes,” says Ulf Hannelius, CEO of Diamyd Medical. “With Precision Medicine at our hands, we’re closer than ever to therapies that address the root cause of the disease.”

The discussion, moderated by Biostock (www.biostock.se), will be broadcast live on YouTube on Friday, November 14, starting at 7:00 am ET / 13:00 CET, allowing viewers to follow the conversation and submit questions via chat. The broadcast can be accessed on: https://www.youtube.com/live/19gacO75Aes

Key topics to be discussed include:

• How close the field is to modifying the course of Type 1 Diabetes rather than managing its symptoms.
• The impact of preserving endogenous insulin production on long-term stability and quality of life.
• The convergence of immune tolerance and precision medicine in therapies such as Diamyd Medical’s GAD65-based approach.
• Insights from earlier GAD studies that have shaped the ongoing Phase 3 trial, with results expected around March 2026.
• How awareness of immune-targeted and precision approaches can help reframe Type 1 Diabetes from lifelong management to potential modification.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes. Diamyd^{® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial with potential for an accelerated approval pathway in the US is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 57 clinics in eight European countries and in the US. Significant results in preserving endogenous insulin production have previously been shown in a large genetically predefined patient group – both in a largescale meta-analysis as well as in the Company’s prospective European Phase IIb trial. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.}

Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication on 12:45 CET, November 12, 2025.